LEXINGTON, Mass., Aug. 1, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology companydevoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 38th
About Aldeyra TherapeuticsAldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. The company is also developing other product candidates for autoimmune and metabolic diseases. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Corporate Contact: David McMullin Aldeyra Therapeutics, Inc. Tel: 781-761-4904 ext. 218 firstname.lastname@example.org
Investor Contact: Chris Brinzey Westwicke Partners Tel: 339-970-2843 Chris.email@example.com
Media Contact: Cammy Duong MacDougall Biomedical Communications 781-591-3443 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-present-at-the-38th-annual-canaccord-genuity-growth-conference-300689805.html
SOURCE Aldeyra Therapeutics, Inc.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All